Why does Waldenström macroglobulinemia cause hyperviscosity symptoms like blurry vision, headache, and bleeding?

Waldenström macroglobulinemia causes hyperviscosity because it produces monoclonal IgM, which is a large pentamer that stays mainly in the intravascular space. That raises plasma viscosity and leads to neurologic symptoms such as headache, dizziness, confusion, and stroke-like symptoms, visual findings like blurry vision and retinal hemorrhages, and mucosal bleeding from impaired platelet function and shear effects.

How do you tell Waldenström macroglobulinemia from multiple myeloma on Step 1?

The key distinction is that Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma with an IgM monoclonal gammopathy, whereas multiple myeloma usually involves malignant plasma cells producing IgG or IgA. Waldenström classically has hyperviscosity, neuropathy, and no punched-out lytic bone lesions, while myeloma more typically has lytic lesions, hypercalcemia, and renal failure as prominent features.

What is the first-line treatment for symptomatic hyperviscosity in Waldenström macroglobulinemia?

The immediate treatment is plasmapheresis. It works especially well in Waldenström macroglobulinemia because the pathogenic IgM is largely intravascular, so plasma exchange can remove it quickly. This is the classic move when patients have symptomatic hyperviscosity, including neurologic symptoms, visual changes, or bleeding, while longer-term therapy targets the malignant B-cell clone.

Why can Waldenström macroglobulinemia cause peripheral neuropathy and cold-related immune problems?

Waldenström macroglobulinemia can cause these problems because the IgM paraprotein may act like an autoantibody. It can contribute to a demyelinating peripheral neuropathy, sometimes with anti–myelin-associated glycoprotein activity, and it can also mediate cold agglutinin hemolytic anemia and cryoglobulinemia. Those immune effects help explain findings such as numbness, tingling, Raynaud symptoms, purpura, and arthralgias.

What diagnostic findings support Waldenström macroglobulinemia?

Waldenström macroglobulinemia is supported by a monoclonal IgM spike on serum protein electrophoresis together with bone marrow infiltration by lymphoplasmacytic cells. Patients may also have elevated serum viscosity, anemia, and sometimes rouleaux formation with paraproteins. Many cases also show a MYD88 mutation, often MYD88 L265P, which is supportive of the diagnosis.

Everything You Need to Know About Waldenström macroglobulinemia for Step 1

Waldenström macroglobulinemia (WM) is one of those Step 1 heme/onc entities that feels “rare” until you realize how many classic vignettes it explains: older patient, IgM spike, hyperviscosity, neuropathy, and no lytic bone lesions. If you can quickly separate it from multiple myeloma, CLL, and marginal zone lymphoma—and remember what IgM does physiologically—you’ll pick up easy points.

Quick check · free practice questionStep 2 CK

A 68-year-old man presents with a 6-month history of progressive fatigue and unintentional weight loss. He reports a recent episode of blurry vision accompanied by headache and says that his memory has declined, which is confirmed by his wife. Physical examination is notable for pallor and generalized weakness. Laboratory evaluation shows anemia and an elevated erythrocyte sedimentation rate. Serum protein electrophoresis demonstrates a sharp, narrow monoclonal spike of IgM, and the serum IgM concentration is 6.3 g/dL. Which of the following is the most likely diagnosis?

Where Waldenström Fits (Big Picture)

Waldenström macroglobulinemia is essentially:

A lymphoplasmacytic lymphoma (a B-cell non-Hodgkin lymphoma with plasmacytic differentiation)
That secretes monoclonal IgM
Causing symptoms largely from IgM-related hyperviscosity and immune effects

High-yield one-liner:
WM = lymphoplasmacytic lymphoma + IgM monoclonal gammopathy → hyperviscosity, neuropathy, bleeding, cryoglobulinemia.

Definition & Classification

What it is

Waldenström macroglobulinemia is a low-grade B-cell neoplasm characterized by:

Bone marrow infiltration by lymphoplasmacytic cells
A circulating monoclonal IgM paraprotein

What it’s NOT (Step 1 traps)

Not multiple myeloma (usually IgG/IgA; lytic lesions, hypercalcemia, renal failure more prominent)
Not MGUS (MGUS is asymptomatic and has lower M-protein burden)
Not CLL/SLL (CD5+ CD23+ small mature lymphocytes; can have hypogammaglobulinemia)

Pathophysiology: Why IgM Causes Such Distinct Symptoms

1) IgM structure → hyperviscosity

IgM is a pentamer, so it is large and stays mainly intravascular. That makes it a prime culprit for increased plasma viscosity.

Clinical consequences of hyperviscosity:

Neurologic: headache, dizziness, confusion, stroke-like symptoms
Visual: blurry vision, “sausage-link” retinal veins, retinal hemorrhages
Bleeding: mucosal bleeding (epistaxis, gingival bleeding) due to impaired platelet function and shear effects

2) IgM can behave like an autoantibody

IgM paraproteins may bind to various targets, producing:

Peripheral neuropathy (classically demyelinating; sometimes anti–myelin-associated glycoprotein [MAG] activity)
Cold agglutinin hemolytic anemia (IgM-mediated RBC agglutination at cold temps)
Cryoglobulinemia (precipitation in the cold) → Raynaud, purpura, arthralgias, renal disease (more often mixed cryoglobulinemia overall, but WM can contribute)

3) Marrow infiltration → cytopenias

Bone marrow involvement can cause:

Anemia (common)
Thrombocytopenia and leukopenia (less common but possible)

HY genetic association

Many cases have MYD88 mutation (often MYD88 L265P), which drives NF-κB signaling and B-cell survival.

Clinical Presentation (How It Shows Up in Vignettes)

Classic symptom clusters

Hyperviscosity syndrome

Headache, vision changes, vertigo, confusion
Mucosal bleeding
Retinal hemorrhages

Neuropathy

Distal symmetric sensory symptoms (numbness/tingling)
Can be chronic and progressive

B symptoms

Fever, night sweats, weight loss (variable; often indolent)

Organomegaly/lymphadenopathy

Can occur (it’s a lymphoma), but often less dramatic than aggressive NHL

Key “separate WM from multiple myeloma” clues

WM typically has:

No punched-out lytic lesions
No prominent hypercalcemia from bone destruction
Hyperviscosity is more typical (because IgM is huge)

Diagnosis: What You Need to Recognize Fast

Labs you’ll see

Monoclonal IgM spike on serum protein electrophoresis (SPEP)
Elevated serum viscosity (if tested)
Possible anemia, rouleaux formation may be less emphasized than in myeloma but can occur with paraproteins

Confirmatory testing (board-style)

Diagnosis is supported by:

Bone marrow biopsy: lymphoplasmacytic infiltrate
Immunoglobulin studies: IgM monoclonal gammopathy
Often MYD88 mutation positivity (supportive)

Quick comparison table (high yield)

Feature	Waldenström macroglobulinemia	Multiple myeloma
Cell type	Lymphoplasmacytic lymphoma	Malignant plasma cells
Main Ig	IgM	Usually IgG or IgA
Hyperviscosity	Common	Can happen, but less classic
Bone lesions	Absent	Lytic lesions common
Hypercalcemia	Uncommon	Common (CRAB)
Renal failure	Can occur, but less classic	Classic (light chains, cast nephropathy)
Organomegaly	Can occur	Less typical

Treatment (Step 1 / Step 2 High Yield)

Immediate management: hyperviscosity = plasmapheresis

If symptomatic hyperviscosity is present (neuro/visual/bleeding symptoms), the classic move is:

Plasmapheresis to remove circulating IgM quickly

Why it works well in WM: IgM is largely intravascular, so plasma exchange is effective.

Disease-directed therapy

Definitive treatment targets the malignant B-cell clone. Common regimens include:

Anti-CD20 therapy (e.g., rituximab-based regimens)
BTK inhibitors (e.g., ibrutinib, zanubrutinib) are important in contemporary management (especially with MYD88-driven signaling)
Combination chemoimmunotherapy may be used depending on symptoms/burden

Step-level takeaway:

Acute hyperviscosity → plasmapheresis
Long-term control → B-cell–directed therapy (rituximab ± others; BTK inhibitors)

High-Yield Associations & “Buzzwords”

Buzzwords that should scream WM

“Older adult with IgM monoclonal spike”
Hyperviscosity: blurry vision + headache + mucosal bleeding
“Peripheral neuropathy”
“No lytic bone lesions”

Related immunology/hematology pearls

IgM is the first antibody produced in a primary immune response and is best at complement activation
Pentameric structure explains:
- High molecular weight
- High viscosity
- Mostly intravascular distribution

First Aid Cross-References (What to Flip To)

Use these as “anchor pages” when you review (edition page numbers vary):

Non-Hodgkin lymphomas (indolent B-cell lymphomas; lymphoplasmacytic lymphoma)
Plasma cell dyscrasias (compare to multiple myeloma, MGUS)
Hyperviscosity syndrome (classically IgM-related)
Cold agglutinin disease / autoimmune hemolysis (IgM-mediated)

How First Aid often tests it: WM appears as lymphoplasmacytic lymphoma producing IgM, associated with hyperviscosity, Raynaud/cryoglobulinemia, and neuropathy—and contrasted with myeloma’s CRAB findings and lytic lesions.

Rapid-Fire USMLE Checklist (Memorize These)

Diagnosis core: lymphoplasmacytic lymphoma + monoclonal IgM
Key complication: hyperviscosity (neuro + visual + mucosal bleeding)
Key distinguishing feature: no lytic bone lesions
Acute treatment: plasmapheresis
Path mutation (HY): MYD88 (often L265P)
Extra associations: neuropathy, cryoglobulinemia, cold agglutinins

Mini Vignette Pattern (Practice in Your Head)

Stem: 68-year-old with headaches, blurry vision, epistaxis, fatigue. Labs show anemia and an M-spike. Imaging shows no lytic lesions.
Answer path: Think IgM → hyperviscosity → Waldenström macroglobulinemia → treat acute symptoms with plasmapheresis, then rituximab-based therapy/BTK inhibitor.